Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

Yuan-Kai ShiJianhua ChenHelong ZhangZhihong ZhangYiping ZhangZhehai WangShucai ZhangJian ZhaoChunling LiuXiuwen WangYanqiu ZhaoChanglu HuLei YangXuezhi HaoLin WangYunpeng LiuYan YuJun ZhaoMengzhao WangLiangming ZhangSanyuan SunYanping HuKangsheng GuXiaosheng HangJinlu ShanYu ZhangBangxian TanWeihua YangRunxiang YangMeimei SiHuaize GengHui LiXiaoyan Kang

Published in: BMC medicine (2023)

Center for Drug Evaluation of National Medical Products Administration of China: CTR20190789, registered on April 28, 2019; ClinicalTrials.gov: NCT04641754, registered on November 24, 2020.

Keyphrases

phase ii study
advanced non small cell lung cancer
open label
locally advanced
single cell
healthcare
cell therapy
quality improvement
cross sectional
squamous cell carcinoma
placebo controlled
clinical trial
stem cells
radiation therapy
rectal cancer
bone marrow
study protocol